Long-term investors are going to have to be happy with Bristol-Myers Squibb's
Metric |
2009 |
2010 |
2011 |
2012 |
2013 |
---|---|---|---|---|---|
Actual or projected non-GAAP earnings |
$1.85 |
$2.15-$2.25 |
N/A |
N/A |
At least $1.95 |
Source: Company press releases.
At its investor conference yesterday, Bristol-Myers laid out its plan for the loss of $6.1 billion in revenue after it and marketing partner sanofi-aventis
Bristol -Myers needs each arm of its three-pronged approach to succeed in order to reach that goal.
The first one is easy: cut some costs. As long as it doesn't axe the research and development budget too much, getting leaner seems like a free source of profits for investors.
The second prong is to grow its newer drugs. The company wants to expand the use of leukemia drug Sprycel as a first-line treatment rather than being used after Novartis'
Finally Bristol-Myers expects to launch five new drugs by 2012, assuming the regulatory authorities agree. The biggest of the group might be cancer drug ipilimumab, which Bristol-Myers owns the full rights to after acquiring Medarex. Yesterday the company said it would seek approval this year for the drug to treat advanced melanoma and plans to start a trial testing the drug in lung cancer. Both are hard-to-treat indications, which could mean quick adoption by doctors.
If Bristol-Meyers can hit its target, I have a hard time seeing shares decrease much from here. Essentially investors are getting a bond -- with a yield higher than that of similarly situated Pfizer
Todd Wenning lays out five keys to successful dividend investing.